A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BATTLE
- 26 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 Aug 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2017 as reported by ClinicalTrials.gov
- 16 Sep 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.